Cargando…

Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections

BACKGROUND: Gastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse. Trastuzumab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive tumors. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Laboissiere, Renato Santos, Buzelin, Marcelo Araújo, Balabram, Débora, De Brot, Marina, Nunes, Cristiana Buzelin, Rocha, Rafael Malagoli, Cabral, Mônica Maria Demas Álvares, Gobbi, Helenice
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632681/
https://www.ncbi.nlm.nih.gov/pubmed/26530403
http://dx.doi.org/10.1186/s12876-015-0384-1
_version_ 1782399071410978816
author Laboissiere, Renato Santos
Buzelin, Marcelo Araújo
Balabram, Débora
De Brot, Marina
Nunes, Cristiana Buzelin
Rocha, Rafael Malagoli
Cabral, Mônica Maria Demas Álvares
Gobbi, Helenice
author_facet Laboissiere, Renato Santos
Buzelin, Marcelo Araújo
Balabram, Débora
De Brot, Marina
Nunes, Cristiana Buzelin
Rocha, Rafael Malagoli
Cabral, Mônica Maria Demas Álvares
Gobbi, Helenice
author_sort Laboissiere, Renato Santos
collection PubMed
description BACKGROUND: Gastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse. Trastuzumab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive tumors. However, data on the frequency of HER2-positive cases among Brazilian patients are limited. Our aim was to characterize HER2 protein and gene status in a series of Brazilian patients with gastric cancer and to evaluate its association with clinicopathological data. METHODS: Histological slides from 124 primary gastrectomies were reviewed and their pathological reports were retrieved from the files at a Brazilian university hospital. Automated immunohistochemistry for HER2 was performed on whole-tissue sections from each tumor. HER2-equivocal cases by immunohistochemistry were submitted to automated dual in situ hybridization for gene amplification evaluation. HER2 status was confronted with clinicopathological parameters in order to assess statistically significant associations. RESULTS: Immunohistochemistry analysis revealed that 13/124 cases (10.5 %) were HER2 positive (3+), 10/124 cases (8.1 %) were equivocal (2+) and 101/124 cases (81.4 %) were negative, being 7 cases 1+. None of the equivocal cases showed gene amplification. The overall HER2 positivity rate was 10.5 %. There was an association between HER2 expression and Laurén’s intestinal histological subtype (P = 0.048), well to moderately differentiated tumors (P = 0.004) and presence of lymphovascular invasion (P = 0.031). No association was found between HER2 status and tumor topography. CONCLUSIONS: Confronted with data published by other authors, the lower percentage of HER2-positive cases found in our series might be partially explained by the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gastric carcinomas in Brazilian patients. This could also account for the lack of statistically significant association between HER2 status and tumor topography in our study.
format Online
Article
Text
id pubmed-4632681
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46326812015-11-05 Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections Laboissiere, Renato Santos Buzelin, Marcelo Araújo Balabram, Débora De Brot, Marina Nunes, Cristiana Buzelin Rocha, Rafael Malagoli Cabral, Mônica Maria Demas Álvares Gobbi, Helenice BMC Gastroenterol Research Article BACKGROUND: Gastric cancer is usually diagnosed in an advanced stage of disease and treatment options are sparse. Trastuzumab was recently approved for metastatic or locally advanced carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive tumors. However, data on the frequency of HER2-positive cases among Brazilian patients are limited. Our aim was to characterize HER2 protein and gene status in a series of Brazilian patients with gastric cancer and to evaluate its association with clinicopathological data. METHODS: Histological slides from 124 primary gastrectomies were reviewed and their pathological reports were retrieved from the files at a Brazilian university hospital. Automated immunohistochemistry for HER2 was performed on whole-tissue sections from each tumor. HER2-equivocal cases by immunohistochemistry were submitted to automated dual in situ hybridization for gene amplification evaluation. HER2 status was confronted with clinicopathological parameters in order to assess statistically significant associations. RESULTS: Immunohistochemistry analysis revealed that 13/124 cases (10.5 %) were HER2 positive (3+), 10/124 cases (8.1 %) were equivocal (2+) and 101/124 cases (81.4 %) were negative, being 7 cases 1+. None of the equivocal cases showed gene amplification. The overall HER2 positivity rate was 10.5 %. There was an association between HER2 expression and Laurén’s intestinal histological subtype (P = 0.048), well to moderately differentiated tumors (P = 0.004) and presence of lymphovascular invasion (P = 0.031). No association was found between HER2 status and tumor topography. CONCLUSIONS: Confronted with data published by other authors, the lower percentage of HER2-positive cases found in our series might be partially explained by the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gastric carcinomas in Brazilian patients. This could also account for the lack of statistically significant association between HER2 status and tumor topography in our study. BioMed Central 2015-11-04 /pmc/articles/PMC4632681/ /pubmed/26530403 http://dx.doi.org/10.1186/s12876-015-0384-1 Text en © Laboissiere et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Laboissiere, Renato Santos
Buzelin, Marcelo Araújo
Balabram, Débora
De Brot, Marina
Nunes, Cristiana Buzelin
Rocha, Rafael Malagoli
Cabral, Mônica Maria Demas Álvares
Gobbi, Helenice
Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title_full Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title_fullStr Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title_full_unstemmed Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title_short Association between HER2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
title_sort association between her2 status in gastric cancer and clinicopathological features: a retrospective study using whole-tissue sections
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632681/
https://www.ncbi.nlm.nih.gov/pubmed/26530403
http://dx.doi.org/10.1186/s12876-015-0384-1
work_keys_str_mv AT laboissiererenatosantos associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT buzelinmarceloaraujo associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT balabramdebora associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT debrotmarina associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT nunescristianabuzelin associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT rocharafaelmalagoli associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT cabralmonicamariademasalvares associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections
AT gobbihelenice associationbetweenher2statusingastriccancerandclinicopathologicalfeaturesaretrospectivestudyusingwholetissuesections